Kythera Pharmaceuticals Purchases Rights to PGD2 Blocking Drug “Setipriprant” for Hair Loss
Last week, [tag]Kythera[/tag] pharmaceuticals purchased the rights to “[tag]setipriprant[/tag],” a [tag]prostaglandin D2[/tag] ([tag]PGD2[/tag]) drug for the treatment of [tag]hair loss[/tag]. The PGD2 theory of hair loss was initially proposed by Dr. [tag]George Cotsarelis[/tag] at the University of Pennsylvania in 2012. Cotsarelis and his team found elevated PGD2 levels in bald scalp compared to non-balding scalp. Cotsarelis […]
